News
Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...
Zacks Investment Research on MSN9h
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease DrugGSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback